TYME News and Press, Tyme Technologies Inc.

Shareholders of Syros Pharmaceuticals ( NASDAQ: SYRS ) and Tyme Technologies ( NASDAQ: TYME ) on Thursday voted in favor of the merger between the two biotech companies. SYRS and TYME stock gained more than 20% each in aftermarket trading - SYRS +22% and TY...

-- Combined Company to Trade on Nasdaq Under Ticker “SYRS” -- -- Syros Announces 1-for-10 Reverse Stock Split of Common Stock -- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and ...

BEDMINSTER, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME) (“Tyme” or the “Company”), today announced that independent proxy advisory firms Glass, Lewis & Co. (“Glass Lewis”) and Institutional Shareholder Services...

Companies focused on a class of drugs known as T-cell engagers are trading higher Tuesday after AstraZeneca ( NASDAQ: AZN ) announced an agreement to acquire the U.S.-based TeneoTwo for a total consideration of up to $1.3B. The acquisition will further diversify its hema...

Penny stocks are shares of companies trading for less than $5 and have offered speculative potential during the stock market crash this year. They’re known for their high-risk and high reward, and when it comes to a choppy stock market, as we’ve seen recently, traders seek...

Development stage biotech firms Syros Pharmaceuticals ( SYRS ) and Tyme Technologies ( NASDAQ: TYME ) announced on Tuesday that the companies entered into a definitive merger agreement following which Syros ( SYRS ) will acquire Tyme ( TYME ). Tyme ( TYME )...

Combined Company Will Operate as Syros Pharmaceuticals and Continue to Advance Syros’ Ongoing Clinical Programs Syros Expects to Have Cash Into 2025; At Least a Year Past SELECT-MDS-1 Pivotal Data Now Planning to Initiate Phase 3 Clinical Trial o...

Tyme Technologies is a clinical-stage biopharma company trading at a large discount to net cash + marketable securities. After the company discontinued the development of its primary compound, they have announced exploration of strategic alternatives. Board seems to be leaning tow...

Tyme Technologies press release (NASDAQ:TYME): FY Non-GAAP EPS of -$0.13. As of March 31, 2022, the Company had approximately $84.0 million in cash and marketable securities, compared to $92.0 million as of December 31, 2021. For further details see: Tyme Technologies Non-GAAP EPS of -$...

BEDMINSTER, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and operating results for its fourth fiscal quarter and full y...